Delving into the Latest Updates on Pharma King Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Immune System Diseases

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3

选择 Boehringer Ingelheim Pharma GmbH &Co.生产的替米沙坦氢氯噻嗪片(商品名:Micardis Plus 美嘉素，规格:每片含替米沙坦 80mg.氢氯噻嗪 12.5mg)作为参比制剂，对韩国 DASAN 制药有限公司研制的替米沙坦氢氯噻嗪片进行餐后给药条件下人体生物等效性试验，用于评价其与参比制剂的人体生物等效性。

[Translation]

Telmisartan and hydrochlorothiazide tablets (trade name: Micardis Plus, specifications: each tablet contains 80 mg of telmisartan and 12.5 mg of hydrochlorothiazide) produced by Boehringer Ingelheim Pharma GmbH & Co. were selected as the reference preparation. A human bioequivalence study was conducted on the telmisartan and hydrochlorothiazide tablets developed by DASAN Pharmaceutical Co., Ltd. of South Korea under the condition of postprandial administration to evaluate its human bioequivalence with the reference preparation.

Start Date26 Jun 2019

Sponsor / Collaborator

Pharma King Co., Ltd.

[+2]

CTR20190776 / CompletedNot Applicable

替米沙坦氢氯噻嗪片空腹人体生物等效性试验

[Translation] Bioequivalence study of telmisartan and hydrochlorothiazide tablets in fasting volunteers

选择 Boehringer Ingelheim Pharma GmbH &Co.生产的替米沙坦氢氯噻嗪片(商品名:Micardis Plus 美嘉素，规格:每片含替米沙坦 80mg.氢氯噻嗪 12.5mg)作为参比制剂，对韩国 DASAN 制药有限公司研制的替米沙坦氢氯噻嗪片进行空腹给药条件下人体生物等效性试验，用于评价其与参比制剂的人体生物等效性。

[Translation]

Telmisartan and hydrochlorothiazide tablets (trade name: Micardis Plus, specifications: each tablet contains 80 mg of telmisartan and 12.5 mg of hydrochlorothiazide) produced by Boehringer Ingelheim Pharma GmbH & Co. were selected as the reference preparation. A human bioequivalence study on the telmisartan and hydrochlorothiazide tablets developed by DASAN Pharmaceutical Co., Ltd. of South Korea was carried out under fasting conditions to evaluate its human bioequivalence with the reference preparation.

Start Date12 Jun 2019

Sponsor / Collaborator

Pharma King Co., Ltd.

[+2]

100 Clinical Results associated with Pharma King Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Pharma King Co., Ltd.

Login to view more data

100 Deals associated with Pharma King Co., Ltd.

Login to view more data

100 Translational Medicine associated with Pharma King Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Phase 2 Clinical

Phase 3 Clinical

1

7

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

PMK-N01GI1	Nonalcoholic Steatohepatitis More	Phase 3
PMK-M02GI1	Fatty Liver, Alcoholic More	Phase 2
PMK-M01RS1	Asthma More	Phase 1
PMK-L01	Well Aging More	Pending
PMK-N02RS1	Bronchitis, Chronic More	Pending